Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment
Authors:
- 1 May 2019
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- Vol. 39 (39) , 374-387
Abstract
Historically, patient experience, including symptomatic toxicities, physical function, and disease-related symptoms during treatment or their perspectives on clinical trials, has played a secondary role in cancer drug development. Regulatory criteria for drug approval require that drugs are safe and effective, and almost all drug approvals have been based only on efficacy endpoints rather than on quality-of-life (QoL) assessments. In contrast to Europe, information regarding the impact of drugs on patients’ QoL is rarely included in oncology drug labeling in the United States. Until recently, patient input and preferences have not been incorporated into the design and conduct of clinical trials. In recent years, a more in-depth understanding of cancer biology, as well as regulatory changes focused on expediting cancer drug development and approval, has allowed earlier access to novel therapeutic agents. Understanding the implications of these expedited programs is important for oncologists and patients, given the rapid expansion of these programs. In this article, we provide an overview of the role of QoL in the regulatory drug–approval process, key issues regarding trial participation from the patient perspective, and the implications of key expedited approval programs that are increasingly being used by regulatory bodies for cancer care.Keywords
This publication has 83 references indexed in Scilit:
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- The Brief Pain Inventory and Its “Pain At Its Worst in the Last 24 Hours” Item: Clinical Trial Endpoint ConsiderationsPain Medicine, 2010
- Disappointment and drop-out rate after being allocated to control group in a smoking cessation trialContemporary Clinical Trials, 2010
- Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancerAnnals of Oncology, 2009
- Evolution of the Randomized Controlled Trial in Oncology Over Three DecadesJournal of Clinical Oncology, 2008
- Endpoints for Assessing Drug Activity in Clinical TrialsThe Oncologist, 2008
- Reflections on Medical Oncology: 25 Years of Clinical Trials—Where Have We Come and Where Are We Going?Journal of Clinical Oncology, 2008
- Patient-Reported Outcomes Supporting Anticancer Product ApprovalsJournal of Clinical Oncology, 2007
- Longer Consent Forms for Clinical Trials Compromise Patient Understanding: So Why Are They Lengthening?Journal of Clinical Oncology, 2007
- Quality of informed consent in cancer clinical trials: a cross-sectional surveyThe Lancet, 2001